Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05348577 · ClinicalTrials.gov registry record · Phase 3
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase 3 study of Prostate Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
- 20
- Study locations
NCT05348577: Active Phase 3 study of Prostate Cancer, sponsored by AstraZeneca.
NCT05348577 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,035 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05348577, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.
Primary Outcome
Overall survival is defined as time from randomisation until the date of death due to any cause.
Conditions Studied
Interventions
- OTHER placebo
- DRUG docetaxel
- DRUG capivasertib
Study Locations (20)
California
- Research Site - Beverly Hills
- Research Site - Cerritos
- Research Site - Fresno
- Research Site - Los Angeles
- Research Site - Sacramento
- Research Site - San Francisco
- Research Site - Santa Barbara
- Research Site - Santa Monica
- Research Site - Santa Rosa
Colorado
- Research Site - Aurora
- Research Site - Lakewood
- Research Site - Littleton
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
Minnesota
- Research Site - Minneapolis
- Research Site - Minneapolis
New York
- Research Site - Albany
- Research Site - The Bronx
Arizona
- Research Site - Yuma
New Jersey
- Research Site - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2026-03-04 |
| Phase | Phase 3 |
What the registry record for NCT05348577 still lists
NCT05348577 is an interventional study that assigns participants to a tested intervention. Its 1,035 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT05348577 names 20 study sites across 7 states, led by California, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT05348577 about?
NCT05348577 is a clinical study titled "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)". This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The int...
What is the current status of trial NCT05348577?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2022-03-25. Estimated completion is 2026-03-04.
What conditions does trial NCT05348577 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05348577?
The interventions under investigation include: placebo (OTHER), docetaxel (DRUG), capivasertib (DRUG).
Who is sponsoring clinical trial NCT05348577?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05348577 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05348577's enrollment target sits among peer trials
1,035 54th of 735 higher than 682 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI